相关实验视频

Updated: Jul 19, 2025

Generation of Human CD40-activated B cells

Generation of Human CD40-activated B cells

Published on: October 16, 2009

与OX40激动剂联合免疫疗法的发展中的挑战和机遇

William L Redmond¹

¹Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.

Expert opinion on biological therapy

|August 17, 2023

概括

OX40激动剂增强T细胞功能和抗瘤免疫力. 然而,它们在晚期癌症的临床疗效是有限的,需要新的组合策略来改善治疗结果.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

OX40 (CD134) 是T细胞上的共刺激受体,对它们的生存和功能至关重要.
在临床前模型中,OX40激动剂在刺激抗瘤免疫力方面表现有前途.
在晚期恶性瘤中观察到OX40激动剂的临床成功有限.

研究的目的:

审查目前OX40激动剂组合免疫治疗的现状.
分析OX40激动剂治疗的临床前和临床试验数据.
确定局限性并提出替代策略,以提高OX40激动剂的疗效.

主要方法:

临床前研究的文献综述.
对最近临床试验数据的分析.
讨论OX40表达和功能的生物机制.

主要成果:

作为单疗法或免疫检查点阻塞,OX40激动剂尚未达到显著的临床活性.
诸如服用时间,药物的效力和药剂选择等因素可能会限制疗效.
了解OX40的生物学是开发更有效的组合疗法的关键.

结论:

目前的OX40激动剂免疫疗法需要优化临床益处.
需要新的组合药物和策略来提高治疗疗效.
对OX40在T细胞调节中的作用的进一步研究可以指导未来的治疗开发.

关键词:

在 CTLA-4 中.在OX40中,OX40是什么?在PD-1中使用PD-1.在PD-L1中.临床试验是指临床试验中的临床试验.整体刺激的代谢刺激免疫检查点封锁封锁免疫疗法免疫疗法

更多相关视频

Murine Model of CD40-activation of B cells

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...